It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Social Anxiety Disorder Treatment Study

Clinical Trial Title: 
Dose timing of d-cycloserine to augment CBT for social anxiety disorder.
Clinical Trial Protocol ID: 
13121006
Clinical Trial Investigator Name: 
Mark Pollack, MD
Clinical Trial Protocol Description: 

The purpose of this study is to find out if d-cycloserine (DCS) improves the effectiveness of cognitive behavioral therapy (CBT) in reducing symptoms associated with social anxiety disorder. During this 6-week study, participants will receive five sessions of cognitive behavioral therapy; and at four of these sessions, participants will take either DCS or a placebo (an inactive pill). Throughout the study, participants’ symptoms will be assessed using questionnaires, interviews, and lab tests. Participants will also be asked to attend a one month and a three month follow-up visit.  All study-related procedures, psychiatric evaluation, medication, therapy, and transportation are free.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Be male or female outpatients, > 18 years of age.
  • Have a primary psychiatric diagnosis (designated by the patient as the most important source of current distress) of social anxiety disorder as defined by DSM-5 criteria.

This is a partial list of inclusion criteria. 

Clinical Trial Area: 
Mental Health Disorders
Contact Phone: 
(312) 563-6687
Contact Name: 
Mara Lewis